Alnylam Pharma (ALNY) Tops Q2 EPS by 30c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $286.41 --0%
Revenue Growth %: +70.6%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +70.6%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($1.30), $0.30 better than the analyst estimate of ($1.60). Revenue for the quarter came in at $220.1 million versus the consensus estimate of $193.18 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
- OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
